Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
47
SPHDF Quote, Financials, Valuation and Earnings
Last price:
$16.28
Seasonality move
:
11.09%
Day range:
$16.28 - $16.28
52-week range:
$9.42 - $19.00
Dividend yield:
0%
P/E ratio:
1.45x
P/S ratio:
3.68x
P/B ratio:
7.72x
Volume:
--
Avg. volume:
73
1-year change:
72.82%
Market cap:
$211.2M
Revenue:
$44.4M
EPS (TTM):
-$4.43
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Santhera Pharmaceuticals Holding AG has -- downside to fair value with a price target of -- per share.
SPHDF vs. S&P 500
-
Over the past 5 trading days, Santhera Pharmaceuticals Holding AG has overperformed the S&P 500 by 4.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Santhera Pharmaceuticals Holding AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Santhera Pharmaceuticals Holding AG has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Santhera Pharmaceuticals Holding AG reported revenues of --.
Earnings Growth
-
Santhera Pharmaceuticals Holding AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Santhera Pharmaceuticals Holding AG reported earnings per share of --.
Enterprise value:
233.7M
EV / Invested capital:
--
Price / LTM sales:
3.68x
EV / EBIT:
2.35x
EV / Revenue:
5.30x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.82x
Price / Operating cash flow:
3.49x
Enterprise value / EBITDA:
2.24x
Gross Profit (TTM):
$6.6M
Return On Assets:
66.59%
Net Income Margin (TTM):
-133.87%
Return On Equity:
276.68%
Return On Invested Capital:
123.12%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2017-12-31 | 2018-12-31 | |
| Income Statement | ||||||
| Revenue | $19.2M | -- | -- | $6.7M | $8.1M | |
| Gross Profit | $15.3M | -- | -- | $5.6M | $7M | |
| Operating Income | -$33.6M | -- | -- | -$16.5M | -$14.3M | |
| EBITDA | -$30.4M | -- | -- | -$16.1M | -$14.2M | |
| Diluted EPS | -$57.33 | -- | -- | -$29.37 | -$16.77 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.6M | $15.3M | $11.9M | $37.4M | -- | |
| Total Assets | $87.1M | $83.6M | $70.1M | $120.4M | -- | |
| Current Liabilities | $48.5M | $40.4M | $86M | $59M | -- | |
| Total Liabilities | $78M | $98.1M | $117.7M | $67M | -- | |
| Total Equity | $9.1M | -$14.5M | -$47.6M | $53.5M | -- | |
| Total Debt | $44.5M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-09-30 | 2017-09-30 | 2018-09-30 | 2017-09-30 | 2018-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$33.1M | -$33.5M | |
| Cash From Investing | -- | -- | -- | -$22.2M | $8.8M | |
| Cash From Financing | -- | -- | -- | $59.3M | -$1.2M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SPHDF
Sector
Market Cap
$211.2M
$23.4M
Price % of 52-Week High
85.68%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.64%
1-Year Price Total Return
72.82%
-21.81%
Beta (5-Year)
-0.796
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.04
200-day SMA
Buy
Level
$15.30
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$15.34
Relative Strength Index (RSI14)
Buy
Level
99.38
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$14.14
MACD (12, 26)
Buy
Level
4.50
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.3647)
Sell
CA Score
(Annual)
Level (-2.2239)
Sell
Beneish M-Score
(Annual)
Level (41.3444)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.1885)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.
Stock Forecast FAQ
In the current month, SPHDF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SPHDF average analyst price target in the past 3 months is --.
-
Where Will Santhera Pharmaceuticals Holding AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Santhera Pharmaceuticals Holding AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Santhera Pharmaceuticals Holding AG?
Analysts are divided on their view about Santhera Pharmaceuticals Holding AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Santhera Pharmaceuticals Holding AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Santhera Pharmaceuticals Holding AG's Price Target?
The price target for Santhera Pharmaceuticals Holding AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SPHDF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Santhera Pharmaceuticals Holding AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SPHDF?
You can purchase shares of Santhera Pharmaceuticals Holding AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Santhera Pharmaceuticals Holding AG shares.
-
What Is The Santhera Pharmaceuticals Holding AG Share Price Today?
Santhera Pharmaceuticals Holding AG was last trading at $16.28 per share. This represents the most recent stock quote for Santhera Pharmaceuticals Holding AG. Yesterday, Santhera Pharmaceuticals Holding AG closed at $16.28 per share.
-
How To Buy Santhera Pharmaceuticals Holding AG Stock Online?
In order to purchase Santhera Pharmaceuticals Holding AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SPHDF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SPHDF
Sector
P/E ratio
1.45x
23.34x
PEG ratio
--
-0.01x
P/B ratio
7.72x
1.72x
Price / LTM sales
3.68x
1.51x
Growth Metrics
SPHDF
Sector
Revenue growth
--
3.21%
Earnings growth
--
10.12%
Revenue (5-year growth)
-10.15%
6.27%
Earnings forecast
--
-$0.19
Profitability
SPHDF
Sector
Profitability FY 2024
$26M
$2.7M
Return on invested capital
123.12%
-33.62%
Return on assets
66.59%
-29.68%
Return on equity
276.68%
-38.89%
Earnings Date
Last Earnings Date
Feb
13
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
SPHDF
Sector
Total cash
$18.3M
$25M
Short term investments
--
$23.9M
Total assets
$168.3M
$72.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
66
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
